According to current evidence, Alzheimer’s disease (AD) is a disease continuum with a 10-20-year pre-symptomatic phase preceding the onset of dementia. The International Working Group (IWG) on research diagnostic criteria for AD provided in 2007 a new framework where the presence of biomarkers characteristic of AD, albeit not mandatory for diagnosis, provides additional proof of diagnosis in the absence of clear clinical manifestations. These IMI projects will work closely with other related research initiatives, such as the UK Dementias Platform and the Global Alzheimer’s Platform (GAP). Markku Toivonen, Scientific Director at NDA Group AB, demonstrates that these ongoing and novel collaborations hold promise that effective preventive and treatment measures for AD could be found and appropriately targeted.
https://www.jforcs.com/7/wp-content/uploads/2016/01/Industry-and-Academia….pdf